Cargando…

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice

BACKGROUND AND AIMS: Modified Vaccinia virus Ankara (MVA) represents a promising vaccine vector for respiratory administration to induce protective lung immunity including tertiary lymphoid structure, the bronchus-associated lymphoid tissue (BALT). However, MVA expressing the severe acute respirator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Do, Kim Thi Hoang, Willenzon, Stefanie, Ristenpart, Jasmin, Janssen, Anika, Volz, Asisa, Sutter, Gerd, Förster, Reinhold, Bošnjak, Berislav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580083/ https://www.ncbi.nlm.nih.gov/pubmed/37854858 http://dx.doi.org/10.3389/fcimb.2023.1259822

Ejemplares similares

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents
por: Bošnjak, Berislav, et al.
Publicado: (2021)

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
por: Tscherne, Alina, et al.
Publicado: (2021)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
por: Veit, Svenja, et al.
Publicado: (2018)

Application of light sheet microscopy for qualitative and quantitative analysis of bronchus-associated lymphoid tissue in mice
por: Mzinza, David Twapokera, et al.
Publicado: (2018)

Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
por: Langenmayer, Martin C., et al.
Publicado: (2023)

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2023)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
por: Kalodimou, Georgia, et al.
Publicado: (2019)

Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
por: Förster, Reinhold, et al.
Publicado: (2020)

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST
por: Fathi, Anahita, et al.
Publicado: (2023)

MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination
por: Meyer zu Natrup, Christian, et al.
Publicado: (2023)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
por: Altenburg, Arwen F., et al.
Publicado: (2014)

Robust induction of neutralizing antibodies against the SARS‐CoV‐2 Delta variant after homologous Spikevax or heterologous Vaxzevria‐Spikevax vaccination
por: Hammerschmidt, Swantje I., et al.
Publicado: (2022)

Omicron infection-associated T- and B-cell immunity in antigen-naive and triple-COVID-19-vaccinated individuals
por: Barros-Martins, Joana, et al.
Publicado: (2023)

Hide and seek with SARS-CoV-2: spike receptor-binding domain-specific memory B cells still recognize Omicron variant
por: Odak, Ivan, et al.
Publicado: (2022)

Obstetric Ultrasonography to Detect Fetal Abnormalities in a Mouse Model for Zika Virus Infection
por: Forster, Dominik, et al.
Publicado: (2020)

NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity
por: Barros-Martins, Joana, et al.
Publicado: (2022)

IL-17–induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs
por: Fleige, Henrike, et al.
Publicado: (2014)

Challenges of CRISPR-Based Gene Editing in Primary T Cells
por: Rezalotfi, Alaleh, et al.
Publicado: (2022)

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
por: Barros-Martins, Joana, et al.
Publicado: (2021)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
por: Morelli, María Paula, et al.
Publicado: (2020)

E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox
por: Volz, Asisa, et al.
Publicado: (2018)

Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise
por: Kubinski, Mareike, et al.
Publicado: (2020)

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
por: Behrens, Georg M. N., et al.
Publicado: (2022)

Cardiomyocytes display low mitochondrial priming and are highly resistant toward cytotoxic T‐cell killing
por: Zheng, Xiang, et al.
Publicado: (2016)

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
por: Fathi, Anahita, et al.
Publicado: (2022)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses
por: Riederer, Stephanie, et al.
Publicado: (2021)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells
por: Halle, Stephan, et al.
Publicado: (2009)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

MvaT binds to the P (exsC) promoter to repress the type III secretion system in Pseudomonas aeruginosa
por: Yin, Liwen, et al.
Publicado: (2023)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Critical Role of Perforin-dependent CD8+ T Cell Immunity for Rapid Protective Vaccination in a Murine Model for Human Smallpox
por: Kremer, Melanie, et al.
Publicado: (2012)

Plasmacytoid dendritic cells induce tolerance predominantly by cargoing antigen to lymph nodes
por: Kohli, Karan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_257vlumo8q3avvq5qvlv5jm1n4